Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dermatitis, Chronic Clear all
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 9:44 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Apremilast and Moderate to Severe Chronic Hand Dermatitis

NCT03741933
View directory record Official record
Conditions
Chronic Hand Dermatitis
Interventions
Apremilast 30mg
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Jul 22, 2026, 9:44 PM EDT
Completed No phase listed Observational

Evaluating for Contact Allergies in Patients With Chronic Urticaria

NCT00868036
View directory record Official record
Conditions
Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
Interventions
Patch Testing
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Ruxolitinib in Chronic Hand Dermatitis

NCT05293717
View directory record Official record
Conditions
Chronic Hand Dermatitis
Interventions
Ruxolitinib
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634
View directory record Official record
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

NCT03728504
View directory record Official record
Conditions
Chronic Hand Dermatitis
Interventions
ASN002, Placebo Oral Tablet
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Anniston, Alabama • Los Angeles, California • Hialeah, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 9:44 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Placebo, secukinumab (AIN457), etanercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis

NCT00667056
View directory record Official record
Conditions
Dermatitis
Interventions
tacrolimus ointment, placebo ointment
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
17 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Shawnee, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 22, 2026, 9:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

NCT03568331
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tempe, Arizona • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

NCT00817063
View directory record Official record
Conditions
Eczema
Interventions
alitretinoin, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

NCT00828464
View directory record Official record
Conditions
Hand Dermatosis
Interventions
clobetasol propionate
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Jul 22, 2026, 9:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 22, 2026, 9:44 PM EDT
Withdrawn Phase 3 Interventional

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

NCT05219864
View directory record Official record
Conditions
Hand Eczema
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Encino, California • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT04018027
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

NCT05104723
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
Interventions
XELJANZ (tofacitinib)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

NCT01806662
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ustekinumab, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 22, 2026, 9:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis

NCT00691366
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

NCT05906628
View directory record Official record
Conditions
Hand Eczema
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Phoenix, Arizona • Fountain Valley, California • Huntington Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 9:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 22, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

NCT03680131
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%
Drug
Lead sponsor
Edesa Biotech Inc.
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
14
States / cities
Long Beach, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jul 22, 2026, 9:44 PM EDT